原代巨噬细胞培养体系

实验要点及说明：

1．本方法适用于贴壁细胞培养，而不适用于悬浮细胞培养，悬浮细胞可使用滴片法； 

2．所使用的盖玻片应该为玻璃**，并经过铬酸洗液处理； 

3．盖玻片非常薄，易碎，取放盖玻片时动作要轻； 

4．如果需要更多生长状态一致的细胞，可以使用较大的培养皿，但不宜过大，以避免培养液的浪费和增加污染机率； 

5．如果细胞贴壁生长能力较差，可将盖玻片在0.5%多聚赖氨酸溶液中浸泡5-10分钟并自然晾干。

培养方法

传代方法 将旧培养液吸除，PBS清洗两遍后，加入6mL（/100mm皿）胰酶，在显微镜下观察，期间禁止摇晃培养皿，细胞刚有脱落时，则吸除大部分胰酶，留约0.5mL，移至培养箱消化，约2min取出。传代用12mL CM1-1培养液终止消化，轻轻吹打均匀细胞，后可分3~6皿培养；

生长条件 37℃，5%CO2，CM1-1培养液。CM1-1培养液：90%DMEM-H+10%FBS。DMEM-H：DMEM高糖培养液，含谷氨酰胺，含丙酮酸钠。

存储条件 冻存则用6mL冻存液（90%FBS+10%DMSO）终止消化，吹打均匀，分为6支冻存管，用程序降温盒于-80℃冻存，过夜转移至液氮中保存。

我司常期代理ATCC Acris  abcam  cst  Biorbyt  santa  Novus  sigma  lifespan  NEB  roche  ABI  R&D millipore   BD  Qiagen Cayman  Jackson Life  GeneTex   Bio-Rad DSHB  tocris   peprotech 等品牌；部分产品现货，超低比价，货期短，价格优，公司产品仅用于科研售后齐全。

培养操作步骤 ：

1．用盖片镊将盖玻片自75%乙醇中取出，用无菌丝绸布擦拭干净，不要用纱布； 

2．将盖玻片轻轻放入6孔培养板（每孔一片）或培养皿中（每个平皿可放置2-3片）； 

3．在距离紫外灯直射范围内20-30 厘米处照射2-3小时； 

4．将经过计数的细胞悬浮液移入培养板中，使盖玻片完全浸在培养液中； 

5．将培养板在5% CO2水浴孵箱中37℃孵育2-3天，当贴壁细胞生长至覆盖培养板底部2/3面积时，将培养板取出，用盖片镊轻轻取出盖玻片，用蒸馏水漂洗后即可进行快速固定以及细胞化学检测。 

细胞培养方法：

1、细胞传代：细胞密度达到80-90%时即可传代

①弃去培养上清，用PBS或生理盐水清洗1-2次；

②加入2ml0.25%胰酶（T25瓶），使胰酶覆盖整个瓶或皿，盖好放入培养箱消化；

③1-2min后，显微镜下观察细胞，若大部分细胞回缩且有少量细胞脱落，轻轻吹打下确认消化情况后加入完全培养基终止消化；若细胞还是贴壁，放回培养箱继续消化至可以轻轻吹打下为止；

④将细胞悬液1000RPM左右条件下离心4min，弃上清；

⑤用新鲜培养基重悬后加入培养瓶或皿中，T25培养瓶加6-8ml培养基；

⑥悬浮细胞直接离心收集，细胞沉淀重悬后分到新培养瓶中。

2、细胞复苏：

①将冻存管在37℃温水中快速摇晃融化，时间1min左右，加入4-5ml培养基混匀。

②在1000RPM左右条件下离心4min，弃上清,加1-2ml培养基吹匀，将细胞悬液加入培养瓶中，补加适量培养基。

3、细胞冻存：待细胞生长状态良好时进行细胞冻存保种

①弃去培养上清，用PBS或生理盐水清洗1-2次，加入1mL 0.25%胰蛋白酶（T25瓶）

②1-2min后，显微镜下观察细胞，大部分细胞回缩且有少量细胞脱落，轻轻吹打下确认消化情况后加入完全培养基终止消化；

③将细胞悬液1000RPM左右条件下离心4min，弃上清，加1ml冻存液重悬细胞；

④将冻存管放入程序降温盒，放入-80℃冰箱，4小时后将冻存管转入液氮罐储存。

Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.

Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.

Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease. [DISEASE] Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.

Defects in MAPT are a cause of Parkinson-dementia syndrome (PARDE) [MIM:260540]. A syndrome characterized by parkinsonism tremor, rigidity, dementia, ophthalmoparesis and pyramidal signs. Neurofibrillary degeneration occurs in the hippocampus, basal ganglia and brainstem nuclei.

Similarity : Contains 4 Tau/MAP repeats.

Database links : UniProtKB/Swiss-Prot: P10636.5

PHF以神经原纤维缠结(neurofibrillary tangles, NFT)存在于神经元的胞体;以神经毯和神经炎性斑存在于受累神经元的退化树突.微管相关蛋白tau是PHF的主要组成成分.在AD脑中,特别是在PHF结构中的tau被异常过度磷酸化.用磷酸化依赖的特异抗tau抗体检测,已证明PHF中的tau蛋白至少有21个异常磷酸化位点.

英文名称  Anti-PHYH

中文名称  植烷酸氧化酶抗体

别    名  LN1; PAHX; PhyH; PHYH1; Phytanic acid oxidase; phytanoyl CoA 2 hydroxylase; Phytanoyl CoA 2 oxoglutarate dioxygenase; Phytanoyl CoA alpha hydroxylase; Phytanoyl CoA dioxygenase; RD antibody.

浓    度  1mg/1ml

规 格  0.2ml/200μg

抗体来源  Rabbit  

克隆类型  polyclonal

交叉反应  Human, Mouse, Rat, Dog, Cow, Rabbit

产品类型  一抗    

研究领域  肿瘤 细胞生物 学 神经生物学 转录调节因子  

蛋白分子量  predicted molecular weight: 38kDa
原代巨噬细胞培养体系蛋白精氨酸甲基转移酶1检测试剂盒反-氯丹 分析标准品氯T 三水合物 CP,98%

二甲基精氨酸二水解酶1检测试剂盒二基锡 分析标准品氯T 三水合物 ACS, 98%

二甲基精氨酸二水解酶2检测试剂盒二庚基锡 分析标准品氯T 三水合物 AR,99.0%

二甲基精氨酸二水解酶1检测试剂盒倍硫磷 分析标准品溴乙酰二甲缩, 含0.2 % 碳酸稳定剂, 97%

二甲基精氨酸二水解酶2检测试剂盒倍硫磷标准溶液 1.00mg/ml乙酸镁,四水 AR ,99.0%

中性粒趋化因子检测试剂盒倍硫磷标准溶液 100μg/ml,u=4%硫酸镁，七水 AR,99.0%

甲状旁腺检测试剂盒倍硫磷标准溶液 10μg/ml,u=6%硫酸镁，七水 用于分子生物学和植物培养级，≥99.0%